KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Net Margin (2016 - 2025)

Pacira BioSciences has reported Net Margin over the past 16 years, most recently at 0.83% for Q4 2025.

  • Quarterly results put Net Margin at 0.83% for Q4 2025, down 773.0% from a year ago — trailing twelve months through Dec 2025 was 0.97% (up 1517.0% YoY), and the annual figure for FY2025 was 0.97%, up 1517.0%.
  • Net Margin for Q4 2025 was 0.83% at Pacira BioSciences, down from 3.03% in the prior quarter.
  • Over the last five years, Net Margin for PCRX hit a ceiling of 15.2% in Q2 2023 and a floor of 85.11% in Q3 2024.
  • Median Net Margin over the past 5 years was 4.85% (2022), compared with a mean of 0.89%.
  • Biggest five-year swings in Net Margin: crashed -9695bps in 2021 and later skyrocketed 8813bps in 2025.
  • Pacira BioSciences' Net Margin stood at 3.22% in 2021, then surged by 164bps to 2.05% in 2022, then surged by 569bps to 13.72% in 2023, then plummeted by -38bps to 8.57% in 2024, then crashed by -90bps to 0.83% in 2025.
  • The last three reported values for Net Margin were 0.83% (Q4 2025), 3.03% (Q3 2025), and 2.68% (Q2 2025) per Business Quant data.